Results 181 to 190 of about 22,026 (263)

Comparative effects of second-line oral antidiabetic medications on atrial fibrillation risk in patients with type 2 diabetes: a nationwide retrospective cohort study. [PDF]

Cardiovasc Diabetol
Heo GY, Heo SJ, Ko B, Ko YE, Koh HB, Park CH, Park JT, Han SH, Yoo TH, Kang SW, Han M, Kim HW.   +11 more
europepmc   +1 more source

Risk of Dementia in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus DPP-4 Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Endocrinol Diabetes Metab
Kumari K, Bai A, Geeta F, Wadhwani N, Kumar R, Kumar A, Kumari R, Bai L, Muskan F, Kashish F, Yousafzai M.   +10 more
europepmc   +1 more source

The Caenorhabditis elegans DPF-3 and human DPP4 have tripeptidyl peptidase activity. [PDF]

FEBS Lett
Trivedi A, Gudipati RK.
europepmc   +1 more source

Blood Pressure-Lowering Effect of SGLT2 Inhibitors in Patients Without Antihypertensive Treatment: A Real-World Data Analysis. [PDF]

J Clin Hypertens (Greenwich)
Ito R, Satoh M, Hashimoto H, Nobayashi H, Izumi S, Toyama M, Iwabe Y, Suzuki Y, Hirose T, Nakayama S, Murakami T, Sasaki M, Metoki H.   +12 more
europepmc   +1 more source

Association of GLP-1 receptor agonists with intentional self-harm in patients with type 2 diabetes: a Sentinel Distributed Database study. [PDF]

BMJ Open Diabetes Res Care
Kuzucan A, Tran V, Jones JT, Dutcher SK, Her M, Kempner ME, Lee JY, Mosholder A, Round KE, Toh S, Lyons JG.   +10 more
europepmc   +1 more source

Discovery and characterization of novel bioactive peptides from marine secondary products [PDF]

, 2014
Falkenberg, Susan Skanderup
core  

In Vivo Inhibition of Dipeptidyl Peptidase 4 and Neprilysin Activity Enables Measurement of GLP-1 Secretion in Male Rats. [PDF]

J Endocr Soc
Galsgaard KD, Abba V, Kuhre RE, Holst JJ, Hartmann B.   +4 more
europepmc   +1 more source

Cardioprotective glucose-lowering drugs, statins, and risk of first-time atherosclerotic cardiovascular disease in Denmark: a nationwide cohort study. [PDF]

Lancet Reg Health Eur
Ternhamar T, Johansen MØ, Nordestgaard BG, Afzal S.   +3 more
europepmc   +1 more source

SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis.

JAMA Netw Open
Chung MC, Yu TM, Wu LY, Wu MJ, Shieh JJ, Chung CJ.   +5 more
europepmc   +1 more source

Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). [PDF]

PLoS One
Xiong W, Li Y, Huang J, He G, Sun J.
europepmc   +1 more source